MiMedx Group Inc (MDXG)

Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself

Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of...

Form 8-K - Current report

The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends...

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR...

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”...

MIMEDX Announces Launch of G4Derm® Plus

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio G4Derm Plus Added to...

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

MIMEDX Announces First Quarter 2026 Operating & Financial Results

Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations...